New dwarfism drug shows how innovation can be done well
Sara was born on a rainy Sunday, the first child to her adoring and overwhelmed parents. Her mother's pregnancy had been uneventful, and all their antenatal tests normal.
Dec 3, 2015
0
4
Sara was born on a rainy Sunday, the first child to her adoring and overwhelmed parents. Her mother's pregnancy had been uneventful, and all their antenatal tests normal.
Dec 3, 2015
0
4
In a retrospective study believed to be one of the largest of its kind, researchers say they have successfully charted the health risks, growth patterns, and medical and surgical outcomes of 1,374 people with the most common ...
Jun 21, 2021
0
3
A phase three global clinical trial led by the Murdoch Children's Research Institute (MCRI) has shown a new drug boosts bone growth in children born with achondroplasia, the most common type of dwarfism.
Sep 7, 2020
0
12
The US Food and Drug Administration on Friday approved for the first time a drug to improve growth in children with the most common type of dwarfism.
Nov 19, 2021
0
2
A drug that boosts bone growth in children with the most common form of dwarfism may also reduce their chances of sudden infant death syndrome, sleep apnea, and needing surgery, according to a new study.
Nov 21, 2023
0
53
Children with achondroplasia, the most common form of disproportionate short stature, grow taller with trends in improved body proportions after two years of daily vosoritide treatment, a new study analysis finds. Results ...
Mar 20, 2021
0
3
A groundbreaking drug that helps regulate bone development has boosted growth rates in children with achondroplasia—the most common type of dwarfism—in a global trial led by Melbourne's Murdoch Children's Research Institute.
Jun 18, 2019
0
4